121 related articles for article (PubMed ID: 16470409)
1. Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat.
Lu H; Chan KK
Cancer Chemother Pharmacol; 2006 Oct; 58(4):532-9. PubMed ID: 16470409
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
Hong PS; Srigritsanapol A; Chan KK
Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.
Chan KK; Hong PS; Tutsch K; Trump DL
Cancer Res; 1994 Dec; 54(24):6421-9. PubMed ID: 7987837
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic detoxification of phosphoramide mustard by soluble fractions from rat organ tissues.
Hong PS; Chan KK
Drug Metab Dispos; 1991; 19(3):568-73. PubMed ID: 1680621
[TBL] [Abstract][Full Text] [Related]
5. Gas chromatographic-mass spectrometric assay for N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in rat plasma.
Lu H; Chan KK
J Chromatogr B Biomed Appl; 1996 Apr; 678(2):219-25. PubMed ID: 8738025
[TBL] [Abstract][Full Text] [Related]
6. Identification and quantitation of alcophosphamide, a metabolite of cyclophosphamide, in the rat using chemical ionization mass spectrometry.
Hong PS; Chan KK
Biomed Environ Mass Spectrom; 1987 Apr; 14(4):167-72. PubMed ID: 2954602
[TBL] [Abstract][Full Text] [Related]
7. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
8. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
Sladek NE; Doeden D; Powers JF; Krivit W
Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
[TBL] [Abstract][Full Text] [Related]
9. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
Hemminki K
Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
11. Application of a stable-isotope dilution technique to study the pharmacokinetics of human 15N-labelled S-nitrosoalbumin in the rat: possible mechanistic and biological implications.
Warnecke A; Luessen P; Sandmann J; Ikic M; Rossa S; Gutzki FM; Stichtenoth DO; Tsikas D
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May; 877(13):1375-87. PubMed ID: 19070554
[TBL] [Abstract][Full Text] [Related]
12. Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide.
Germann N; Urien S; Rodgers AH; Ratterree M; Struck RF; Waud WR; Serota DG; Bastian G; Jursic BS; Morgan LR
Cancer Chemother Pharmacol; 2005 Feb; 55(2):143-51. PubMed ID: 15592722
[TBL] [Abstract][Full Text] [Related]
13. Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy.
Boal JH; Ludeman SM; Ho CK; Engel J; Niemeyer U
Arzneimittelforschung; 1994 Jan; 44(1):84-93. PubMed ID: 8135883
[TBL] [Abstract][Full Text] [Related]
14. Involvement of a volatile metabolite during phosphoramide mustard-induced ovotoxicity.
Madden JA; Hoyer PB; Devine PJ; Keating AF
Toxicol Appl Pharmacol; 2014 May; 277(1):1-7. PubMed ID: 24642057
[TBL] [Abstract][Full Text] [Related]
15. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans.
Dalvie D; Cosker T; Boyden T; Zhou S; Schroeder C; Potchoiba MJ
Drug Metab Dispos; 2008 Sep; 36(9):1869-83. PubMed ID: 18566038
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of the pharmacokinetics, brain uptake and metabolism of E121, an antiepileptic enaminone ester, in rats.
Khurana M; Salama NN; Scott KR; Nemieboka NN; Bauer KS; Eddington ND
Biopharm Drug Dispos; 2003 Dec; 24(9):397-407. PubMed ID: 14689468
[TBL] [Abstract][Full Text] [Related]
17. Metabolism, pharmacokinetics and excretion of a novel hypoxia activated cytotoxic prodrug, TH-302, in rats.
Jung D; Jiao H; Duan JX; Matteucci M; Wang R
Xenobiotica; 2012 Apr; 42(4):372-88. PubMed ID: 22004352
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats.
Wu WM; Huang F; Lee Y; Buchwald P; Bodor N
J Pharm Pharmacol; 2008 Mar; 60(3):291-7. PubMed ID: 18284808
[TBL] [Abstract][Full Text] [Related]
19. In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs.
Perera MA; Yin D; Wu D; Chan KK; Miller DD; Dalton J
Drug Metab Dispos; 2006 Oct; 34(10):1713-21. PubMed ID: 16815963
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
Jung D; Lin L; Jiao H; Cai X; Duan JX; Matteucci M
Cancer Chemother Pharmacol; 2012 Mar; 69(3):643-54. PubMed ID: 21964906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
